391 related articles for article (PubMed ID: 28123387)
1. Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma.
Jiang Z; Jiang X; Chen S; Lai Y; Wei X; Li B; Lin S; Wang S; Wu Q; Liang Q; Liu Q; Peng M; Yu F; Weng J; Du X; Pei D; Liu P; Yao Y; Xue P; Li P
Front Immunol; 2016; 7():690. PubMed ID: 28123387
[TBL] [Abstract][Full Text] [Related]
2. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma.
Gao H; Li K; Tu H; Pan X; Jiang H; Shi B; Kong J; Wang H; Yang S; Gu J; Li Z
Clin Cancer Res; 2014 Dec; 20(24):6418-28. PubMed ID: 25320357
[TBL] [Abstract][Full Text] [Related]
3. [Construction and function of Glypican-3-targeted fourth-generation chimeric antigen receptor T cells (secreting IL-7 and CCL19)].
Huang W; Liu Y; Hu Y; Gao J
Sheng Wu Gong Cheng Xue Bao; 2020 May; 36(5):979-991. PubMed ID: 32567281
[TBL] [Abstract][Full Text] [Related]
4. GPC3-IL7-CCL19-CAR-T primes immune microenvironment reconstitution for hepatocellular carcinoma therapy.
Lu LL; Xiao SX; Lin ZY; Bai JJ; Li W; Song ZQ; Zhou YH; Lu B; Wu WZ
Cell Biol Toxicol; 2023 Dec; 39(6):3101-3119. PubMed ID: 37853185
[TBL] [Abstract][Full Text] [Related]
5. Development of GPC3 and EGFR-dual-targeting chimeric antigen receptor-T cells for adoptive T cell therapy.
Li K; Qian S; Huang M; Chen M; Peng L; Liu J; Xu W; Xu J
Am J Transl Res; 2021; 13(1):156-167. PubMed ID: 33527015
[TBL] [Abstract][Full Text] [Related]
6. Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3-Targeted Chimeric Antigen Receptor-Engineered T Cells in Hepatocellular Carcinoma.
Liu Y; Di S; Shi B; Zhang H; Wang Y; Wu X; Luo H; Wang H; Li Z; Jiang H
J Immunol; 2019 Jul; 203(1):198-207. PubMed ID: 31142602
[TBL] [Abstract][Full Text] [Related]
7. 32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinoma.
Liu X; Gao F; Jiang L; Jia M; Ao L; Lu M; Gou L; Ho M; Jia S; Chen F; Gao W
J Transl Med; 2020 Aug; 18(1):295. PubMed ID: 32746924
[TBL] [Abstract][Full Text] [Related]
8. Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-Cells plus sorafenib, a case report.
Sun H; Xing C; Jiang S; Yu K; Dai S; Kong H; Jin Y; Shan Y; Yang W; Wang Z; Xiao J; Wang H; Wang W; Li Z; Shi K
Front Immunol; 2022; 13():963031. PubMed ID: 36059488
[TBL] [Abstract][Full Text] [Related]
9. Nonviral mcDNA-mediated bispecific CAR T cells kill tumor cells in an experimental mouse model of hepatocellular carcinoma.
Wang H; Wang X; Ye X; Ju Y; Cao N; Wang S; Cai J
BMC Cancer; 2022 Jul; 22(1):814. PubMed ID: 35879685
[TBL] [Abstract][Full Text] [Related]
10. GPC3-targeted CAR-T cells secreting B7H3-targeted BiTE exhibit potent cytotoxicity activity against hepatocellular carcinoma cell in the in vitro assay.
Cao G; Zhang G; Liu M; Liu J; Wang Q; Zhu L; Wan X
Biochem Biophys Rep; 2022 Sep; 31():101324. PubMed ID: 36032401
[TBL] [Abstract][Full Text] [Related]
11. Molecular phenotypes reveal heterogeneous engraftments of patient-derived hepatocellular carcinoma xenografts.
Zhuo J; Lu D; Wang J; Lian Z; Zhang J; Li H; Cen B; Wei X; Wei Q; Xie H; Xu X
Chin J Cancer Res; 2021 Aug; 33(4):470-479. PubMed ID: 34584372
[TBL] [Abstract][Full Text] [Related]
12. Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma.
Guo X; Jiang H; Shi B; Zhou M; Zhang H; Shi Z; Du G; Luo H; Wu X; Wang Y; Sun R; Li Z
Front Pharmacol; 2018; 9():1118. PubMed ID: 30327605
[TBL] [Abstract][Full Text] [Related]
13. Bispecific CAR-T cells targeting FAP and GPC3 have the potential to treat hepatocellular carcinoma.
Zhou L; Li Y; Zheng D; Zheng Y; Cui Y; Qin L; Tang Z; Peng D; Wu Q; Long Y; Yao Y; Wong N; Lau J; Li P
Mol Ther Oncol; 2024 Jun; 32(2):200817. PubMed ID: 38882528
[TBL] [Abstract][Full Text] [Related]
14. Optimization of GPC3-specific chimeric antigen receptor structure and its effect on killing hepatocellular carcinoma cells.
Zhao J; Lin L; Luo Y; Cai Q; Jiang X; Liao C; Wei H
Bioengineered; 2021 Dec; 12(1):3674-3683. PubMed ID: 34261411
[TBL] [Abstract][Full Text] [Related]
15. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U
Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074
[TBL] [Abstract][Full Text] [Related]
16. BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved anti-cell line derived tumor xenograft activity.
Hickman TL; Choi E; Whiteman KR; Muralidharan S; Pai T; Johnson T; Parikh A; Friedman T; Gilbert M; Shen B; Barron L; McGinness KE; Ettenberg SA; Motz GT; Weiss GJ; Jensen-Smith A
PLoS One; 2022; 17(5):e0266980. PubMed ID: 35507536
[TBL] [Abstract][Full Text] [Related]
17. GPC3-targeted CAR-M cells exhibit potent antitumor activity against hepatocellular carcinoma.
Guan L; Wu S; Zhu Q; He X; Li X; Song G; Zhang L; Yin X
Biochem Biophys Rep; 2024 Sep; 39():101741. PubMed ID: 38881757
[TBL] [Abstract][Full Text] [Related]
18. Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma.
Filmus J; Capurro M
FEBS J; 2013 May; 280(10):2471-6. PubMed ID: 23305321
[TBL] [Abstract][Full Text] [Related]
19. Glypican 3-Targeted Therapy in Hepatocellular Carcinoma.
Nishida T; Kataoka H
Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31510063
[TBL] [Abstract][Full Text] [Related]
20. Glypican-3: A Novel and Promising Target for the Treatment of Hepatocellular Carcinoma.
Zheng X; Liu X; Lei Y; Wang G; Liu M
Front Oncol; 2022; 12():824208. PubMed ID: 35251989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
